Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10784905 | 0.78 | KDM4E (0.31) | KDM4ECYP3A4 | |
| SCHEMBL514835 | 0.76 | — | — | |
| SCHEMBL10626554 | 0.75 | MEN1 (0.32) | TSHR | |
| SCHEMBL10626561 | 0.75 | — | — | |
| Fluoride SCHEMBL776938 | 0.73 | — | — | |
| SCHEMBL18575908 | 0.73 | KDM4E (0.42) | KDM4ECYP3A4CA1USP2TSHR | |
| SCHEMBL24798092 | 0.70 | — | — | |
| SCHEMBL3171358 | 0.70 | — | — | |
| SCHEMBL13218247 | 0.70 | — | — | |
| SCHEMBL13466481 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149545-A1 | HETEROARYLPHENYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-07-17 | — | — | WO | claimed |
| EP-4213843-B1 | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260097047-A1 | Small molecule inhibitors of the ribosome biogenesis factor NVL2 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4709714-A1 | SUBSTITUTED QUINOXALINES | Mirati Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260053792-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2026-02-26 | — | — | US | disclosed |
| US-12559491-B2 | Modified imidazopyridines as glucosylceramide synthase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-24 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4649077-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | Cerevel Therapeutics, LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12458022-B2 | Methods and compositions for use in glued-wood products | ARXADA AG (CH) | 2025-11-04 | — | — | US | disclosed |
| EP-0794218-B1 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENG PLASTICS CORP (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-0753540-B1 | Polycarbonate resin composition | MITSUBISHI ENG PLASTICS CORP (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-6359028-B1 | USED IN MEDICAL EQUIPMENT, DISCOLORATION INHIBITION | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2002-03-19 | — | — | US | disclosed |
| US-20010034419-A1 | Radiation transparent molding materials | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2001-10-25 | — | — | US | disclosed |
| CN-1303385-A | Stable concentrated rare earth carboxylate liquids | RHODIA ELECTRONIC ENGINEERING (US) | 2001-07-11 | — | — | CN | disclosed |
| US-6040367-A | EXCELLENT RESISTANCE TO AN IONIZING RADIATION, IN WHICH HETEROCYCLIC COMPOUND CONTAINING OXYMETHYLENE UNITS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5977206-A | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5948838-A | 0.01 TO 5 PARTS BY WEIGHT OF A COMPOUND CONTAINING OXYMETHYLENE UNIT | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0794218-A2 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0753540-A2 | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559491-B2 | Modified imidazopyridines as glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | KDM4E 2988/4885CYP3A4 3021/4885CA1 1076/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | KDM4E 3467/4885CYP3A4 2215/4885CA1 338/4885 |
| US-20260053792-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TFEB, SNCA, PARK7 | KDM4E 2547/4885CYP3A4 4154/4885CA1 4314/4885 |
| US-20260097047-A1 | Small molecule inhibitors of the ribosome biogenesis factor NVL2 | NOC2L, RPS6, RPS3A | KDM4E 2720/4885CYP3A4 3492/4885CA1 4464/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | KDM4E 1247/4885CYP3A4 4699/4885CA1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.